Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Public ClinicalTrials.gov record NCT03703297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Study identification
- NCT ID
- NCT03703297
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 730 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2018 (Actual)
- Primary completion
- Jan 15, 2024 (Actual)
- Completion
- Oct 23, 2026 (Estimated)
- Last update posted
- Nov 21, 2025
2018 – 2026
United States locations
- U.S. sites
- 34
- U.S. states
- 23
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85715 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Fort Myers | Florida | 33901 | — |
| Research Site | Orange City | Florida | 32763 | — |
| Research Site | St. Petersburg | Florida | 33705 | — |
| Research Site | Marietta | Georgia | 30060 | — |
| Research Site | Hines | Illinois | 60141 | — |
| Research Site | Fort Wayne | Indiana | 46804 | — |
| Research Site | Muncie | Indiana | 47303 | — |
| Research Site | Lexington | Kentucky | 40536 | — |
| Research Site | Annapolis | Maryland | 21401 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | Minneapolis | Minnesota | 55407 | — |
| Research Site | Summit | New Jersey | 07902 | — |
| Research Site | New Hyde Park | New York | 11042 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Sioux Falls | South Dakota | 57104 | — |
| Research Site | Chattanooga | Tennessee | 37404 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Kennewick | Washington | 99336 | — |
| Research Site | Tacoma | Washington | 98405 | — |
| Research Site | Charleston | West Virginia | 25304 | — |
| Research Site | Huntington | West Virginia | 25701 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 149 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03703297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2025 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03703297 live on ClinicalTrials.gov.